Earnings Call · Q1 FY2024·2024-05-09

Q1 24EPS 0.00%·Rev n/aQ4 23EPS -4.65%·Rev n/aQ3 23EPS 0.00%·Rev n/aQ2 23EPS +40.51%·Rev n/a⚠ consensus missing

IOVANCE BIOTHERAPEUTICS, INC. IOVA

Sara Pellegrino — Investor Relations or Communications

Frederick Vogt — Interim President and Chief Executive Officer

James Ziegler — Commercial or Market Access Executive

Igor Bilinsky — Manufacturing Executive

Jean-Marc Bellemin — Chief Financial Officer

Friedrich Graf Finckenstein — Clinical Development Executive

−18.4%1d on move date−18.6% vs SPY3d−20.3%5d−22.5%

Research tier

Behavioral profile computed for 6 speakers on this call.

Sign in to view the Behavioral Lean, the Behavioral Deviation Score, the speaker decomposition, and the novel forward-guidance phrases flagged on this call — each scored against the speaker's own prior-call baseline.

Behavioral data on every earnings call

Per-speaker language deviation, scored against each executive's own history. Explore more IOVA calls or request research access.

More IOVA calls Browse calls Request research access